Pictet Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $87.5M | Buy |
696,122
+308,548
| +80% | +$38.8M | 0.09% | 224 |
|
|
2025
Q1 | $43.1M | Sell |
387,574
-223,545
| -37% | -$24.8M | 0.05% | 336 |
|
|
2024
Q4 | $83.4M | Sell |
611,119
-231,078
| -27% | -$31.5M | 0.09% | 228 |
|
|
2024
Q3 | $97M | Sell |
842,197
-29,127
| -3% | -$3.36M | 0.11% | 201 |
|
|
2024
Q2 | $120M | Sell |
871,324
-210,125
| -19% | -$28.9M | 0.14% | 173 |
|
|
2024
Q1 | $149M | Sell |
1,081,449
-131,864
| -11% | -$18.2M | 0.16% | 164 |
|
|
2023
Q4 | $160M | Buy |
1,213,313
+169,863
| +16% | +$22.4M | 0.18% | 147 |
|
|
2023
Q3 | $117M | Buy |
+1,043,450
| New | +$117M | 0.14% | 176 |
|